Wave Life Sciences (WVE) EBITDA Margin: 2015-2025
Historic EBITDA Margin for Wave Life Sciences (WVE) over the last 7 years, with Jun 2025 value amounting to -579.68%.
- Wave Life Sciences' EBITDA Margin fell 41207.00% to -579.68% in Q2 2025 from the same period last year, while for Jun 2025 it was -258.97%, marking a year-over-year decrease of 19235.00%. This contributed to the annual value of -89.70% for FY2024, which is 3886.00% down from last year.
- Latest data reveals that Wave Life Sciences reported EBITDA Margin of -579.68% as of Q2 2025, which was down 13.60% from -510.30% recorded in Q1 2025.
- Wave Life Sciences' EBITDA Margin's 5-year high stood at 14.67% during Q3 2023, with a 5-year trough of -13,712.28% in Q3 2022.
- In the last 3 years, Wave Life Sciences' EBITDA Margin had a median value of -189.86% in 2024 and averaged -232.37%.
- In the last 5 years, Wave Life Sciences' EBITDA Margin tumbled by 1,369,515bps in 2022 and then surged by 1,372,695bps in 2023.
- Wave Life Sciences' EBITDA Margin (Quarterly) stood at -1,975.18% in 2021, then crashed by 154,499bps to -3,520.18% in 2022, then surged by 346,443bps to -55.75% in 2023, then tumbled by 7,168bps to -167.60% in 2024, then crashed by 41,207bps to -579.68% in 2025.
- Its EBITDA Margin was -579.68% in Q2 2025, compared to -510.30% in Q1 2025 and -167.60% in Q2 2024.